Changes in hepatitis C virus (HCV) viral load and interferon-α levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 3, 2006, Pages 293-297

  Bower, William A ^a,e   Culver, David H ^a   Castor, Delivette ^b   Wu, Yingfeng ^c   James, V Nicole ^a   Zheng, HaoQiang ^a   Hammer, Scott ^b   Kuhnert, Wendi L ^a   Williams, Ian T ^a   Bell, Beth P ^a   Vlahov, David ^c   Dezzutti, Charlene S ^a,d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NEW YORK ACADEMY OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e U S PUBLIC HEALTH SERVICE   (United States)

Author keywords

Coinfection; HAART; Hepatitis C virus; Hepatotoxicity; HIV AIDS; Interferon ; Viral load

Indexed keywords

ALPHA INTERFERON; AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; LIVER ENZYME;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG RESPONSE; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LINEAR REGRESSION ANALYSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SUPERINFECTION; VIRUS LOAD; VIRUS TITRATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD;

EID: 33745893502     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000221689.77220.42     Document Type: Article

References (25)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-62.
2. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831-837.
3. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
4. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr. 2000;24:211-217.
5. Rutschmann OT, Negro F, Hirschel B, et al. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis. 1998;177:783-785.
6. Vento S, Garofano T, Renzini C, et al. Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy. AIDS. 1998;12:116-117.
7. Chung RT, Evans SR, Yang Y, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS. 2002;16:1915-1923.
8. Filippini P, Coppola N, Scolastico C, et al. Can HCV affect the efficacy of anti-HIV treatment? Arch Virol. 2000;145:937-44.
9. Kottilil S, Jagannatha S, Lu A, et al. Changes in hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals. HIV Clin Trials. 2004;5:25-32.
10. Puoti M, Gargiulo F, Roldan EQ, et al. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. J Infect Dis. 2000;181:2033-2036.
11. Ragni MV, Bontempo FA. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis. 1999;180:2027-2029.
12. Rockstroh JK, Theisen A, Kaiser R, et al. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs. AIDS. 1998;12:829-830.
13. Zylberberg H, Chaix ML, Rabian C, et al. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin Infect Dis. 1998;26:1104-1106.
14. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261-1268.
15. Monforte AA, Bugarini R, Pezzotti P, et al, ICONA (Italian Cohort of Naive for Antiretrovirals) Study Group. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr. 2001;28:114-123.
16. Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis. 2003;23:183-194.
17. Torre D, Tambini R, Cadario F, et al. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis. 2001;33:1579-1585.
18. Greenberg B, Berkman A, Thomas R, et al. Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report. J Urban Health. 1999;76:468-480.
19. Cribier B, Schmitt C, Rey D, et al. Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV. Res Virol. 1996;147:263-266.
20. Stylianou E, Aukrust P, Bendtzen K, et al. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol. 2000;119:479-485.
21. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506-1510.
22. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321:1501-1506.
23. Lauer GM, Nguyen TN, Day CL, et al. Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses. J Virol. 2002;76:2817-26.
24. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003;362:1708-1713.
25. Benhamou Y, Di M, Bochet V, et al, MultivirC Group. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology. 2001;34:283-287.